NCT01938235 - Exenatide for Myocardial Protection During Reperfusion Study | Biotech Hunter

Enrollment

198

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

July 31, 2017

Study Completion Date

January 31, 2018

Conditions

Myocardial Infarction

Interventions

DRUG

Exenatide

Intravenous bolus and 24-hour infusion of exenatide

DRUG

Placebo

Intravenous bolus and 24-hour infusion of placebo

Trial Locations (10)

T2N 4Z6

RECRUITING

Foothills Medical Centre, Calgary

T5H 3V9

RECRUITING

Royal Alexandra Hospital, Edmonton

T6G 2B7

RECRUITING

University of Alberta Hospital, Edmonton

L8L 2X2

RECRUITING

Hamilton Health Sciences - General Site, Hamilton

N6A 5A5

RECRUITING

London Health Sciences Centre, London

L3Y 2P7

RECRUITING

Southlake Regional Health Centre, Newmarket

M4N 3M5

RECRUITING

Sunnybrook Health Sciences Centre, Toronto

M5B 1W8

RECRUITING

St. Michael's Hospital, Toronto

M5G 2C4

RECRUITING

Toronto General Hospital, University Health Network, Toronto

G1V 4G5

RECRUITING

Institut universitaire de cardiologie et de pneumologie de Quebec (Hopital Laval), Québec